Puli pharmaceutical expands its production capacity to build an international leading enterprise of pharmaceutical preparations

[China Pharmaceutical network enterprise news] Puli pharmaceutical is an early high-tech enterprise engaged in the research, development, production and sales of international generic drugs in China It is also one of the few leading enterprises in the internationalization of pharmaceutical preparations in China With the continuous development of enterprises, Puli pharmaceutical will create international standards According to the prospectus, the company's turnover in 2016 was more than 200 million yuan, with a total profit of more than 80 million yuan and a net profit of nearly 70 million yuan The funds raised from the IPO of Puli pharmaceutical will be used in two projects One is to build an oral preparation project with an annual output of 1.5 billion tablets in Hangzhou that meets international standards The production of this project is not only for the needs of the domestic market, but also for the international markets such as Europe and the United States; Another project is to expand the original injection production line in Hainan, which meets the European and American standards The completion of this injection will solve the bottleneck of variety production Create international standards for multiple varieties to be listed in the medical insurance catalogue In the production process, Puli pharmaceutical has established a complete GMP management system in accordance with the requirements of FDA, EMA, who and CFDA of China Its production lines have passed the new GMP certification of domestic drugs Its API and freeze-dried powder injection production lines have passed the audit of relevant production quality specifications (cGMP, GMP) of FDA, EMA and who of the United States The small volume injection production lines have passed the EU EMA GMP audit In June 2015, Puli pharmaceutical pharmaceutical preparation production base was recognized as the pilot demonstration project of intelligent manufacturing (Intelligent factory for pharmaceutical preparation production) by the Ministry of industry and information technology of the people's Republic of China At present, Puli pharmaceutical has obtained 47 technologies, including 44 inventions, and 27 product specifications have been listed in the national medical insurance catalog In addition, apart from manufacturing in line with international standards, Puli pharmaceutical has a relatively rich product pipeline, In addition to the core product desloratadine series, it also has many special products, such as diclofenac sodium enteric coated sustained-release capsule, Yiganling liquid capsule, diclofenac sodium enteric coated sustained-release capsule, allopurinol sustained-release tablet, theophylline sustained-release capsule, aspirin dipyridamole sustained-release capsule, dimethylbiguanide sustained-release tablet, asiaticoside cream ointment and other products, covering liver clearing and detoxification, non steroidal anti-inflammatory Respiratory system, blood system and other fields In recent years, the market demand for main products of Puli pharmaceutical has been growing steadily, the business scale has been expanding, and the sales revenue has been increasing From 2014 to 2016, the annual compound growth rate of the company's operating revenue is 22.76%, and the annual compound growth rate of the net profit attributable to the shareholders of the parent company is 37.95%, which shows the company's good growth On January 11, 2017, the prospectus of the company's public offering of shares showed that from January to March 2017, Puli pharmaceutical's expected operating revenue range was 40 million to 44 million yuan, an increase of 11.16% to 22.27% compared with the same period of last year It is estimated that the net profit after deducting non recurring profit and loss will be 8.878 million yuan to 9.694 million yuan, an increase of 7.54% to 17.43% over the same period of last year Although the business scale continues to expand, due to capacity bottlenecks, Puli pharmaceutical mainly focuses on the production of leading products with comparative advantages in the early stage, while other products are less scheduled or not yet produced With the increasing market demand of its products, all kinds of reserved drugs and research projects are gradually registered and approved for production, and the bottleneck of production capacity is becoming the obstacle for its further development Therefore, Puli pharmaceutical plans to use the raised funds to invest in its main projects "the construction project of 1.5 billion tablets / bag / granule production line and R & D center" and "the construction project of European and American standard injection production line" after listing, so as to adapt to the increasing market demand by improving production technology and process flow It is reported that the "European and American standard injection production line construction project" is located in the international and domestic markets, and now has a mature sales model and channels The project plans to build injection production plants and production lines that meet the cGMP certification standards of the United States, the GMP certification of Europe and the new GMP standards of China After completion, it is expected to meet its international order demand After the completion of the "production line and R & D center construction project with an annual output of 1.5 billion tablets / bag / Granule" project, a production capacity of 1.5 billion tablets / bag / granule / pouch will be formed, including 689 million tablets, 333 million capsules and 478 million bags of dry suspension The company selects the varieties with comparative advantages in the subdivision field with relatively high technical difficulty and moderate market scale In addition, by seizing the market opportunity of the shortage of some small varieties of drugs, Puli pharmaceutical is expected to achieve the international registration and sales of its products, which is also conducive to entering the domestic priority approval channel and listing in China more quickly At present, many products still in research and development are favored by foreign sales partners after Puli pharmaceutical passed GMP audit in Europe and America In the future, the company will develop rapidly in a unique way of "taking the foreign market as the new starting point, R & D as the driving force, domestic and international simultaneous registration, and comprehensively driving the domestic and European markets".